Baird Financial Group
PACB icon

Baird Financial Group’s Pacific Biosciences PACB Stock Holding History

Baird Financial Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,204
Closed -$175K – 1839
2022
Q1 		$175K Buy
19,204
+7,827
+69% +$90.1K ﹤0.01% 1762
2021
Q4 		$233K Sell
11,377
-135
-1% -$3.26K ﹤0.01% 1772
2021
Q3 		$294K Buy
+11,512
New +$341K ﹤0.01% 1673

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Baird Financial Group's PACB Position: Q2 2022 in Review

Baird Financial Group sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 19,204 shares — an estimated $175K sold.

Baird Financial Group first reported a position in PACB in Q3 2021 and held it in 3 quarters. The position peaked at $294K in Q3 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Baird Financial Group reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Baird Financial Group sold 19,204 Pacific Biosciences shares in Q2 2022, an estimated $175K.
  • Baird Financial Group first reported a position in Pacific Biosciences in Q3 2021 and held it in 3 quarters.
  • Baird Financial Group's Pacific Biosciences position peaked at $294K in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Baird Financial Group's 13F filing for Q2 2022, filed 8 Aug 2022.